Organic compounds -- part of the class 532-570 series – Organic compounds – Heavy metal containing
Reexamination Certificate
2011-06-28
2011-06-28
Sullivan, Daniel (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heavy metal containing
C562S565000
Reexamination Certificate
active
07968738
ABSTRACT:
The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.
REFERENCES:
patent: 6191123 (2001-02-01), Uckun et al.
patent: 6482815 (2002-11-01), Uckun et al.
patent: 6482816 (2002-11-01), Uckun et al.
patent: 6911471 (2005-06-01), Zingaro et al.
patent: 6995188 (2006-02-01), Zingaro et al.
patent: 7619000 (2009-11-01), Zingaro et al.
patent: 2002/0013371 (2002-01-01), Warrell et al.
patent: 2002/0183385 (2002-12-01), Ellison et al.
patent: 2003/0176359 (2003-09-01), Neuwelt et al.
patent: 2004/0028750 (2004-02-01), Lu
patent: 2005/0131062 (2005-06-01), Zingaro et al.
patent: 1002537 (1998-10-01), None
patent: 188 971 (1966-11-01), None
patent: WO-99/24029 (1998-11-01), None
patent: WO-03/057012 (2003-07-01), None
patent: WO 03/057012 (2003-07-01), None
patent: WO-2006/020048 (2006-02-01), None
West, Anthony R., solid state chemistry and its applications, Wiley, New York, 1988 pp. 358 and 365.
Fatouros, et al., “Preparation and properties of arsonolipid containing liposomes,” Chemistry and Physics of Lipids, 109:75-89 (2001).
American Conference of Governmental Industrial Hygienists, Inc. (ACGIH). Arsenic and soluble compounds, including arsine. Documentation of the Threshold Limit Values and Biological Exposure Indices, sixth edition, 1991.
Aslanidis, et al., “Methylarsino-substituted hydroxy carboxylate esters,” Chemiker-Zeitung, 112(4):125-127 (1988).
Bachleitner-Hofmann et al., “Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia,” Br. J. Haematol., 112(3):783-786 (2001).
Banks, et al., “Biomolecules Bearing the S- or SeAsMe2 Function: Amino Acid and Steroid Derivatives,” Jr. of Medicinal Chemistry, American Chemical Society, 22(5):572-575 (1979).
Barber, Harry J., “Hydrolysis of arylthioarsinites Hydrolysis of arylthioarsinites,” Jr. of the Chemical Society, Abstracts 1365-9 (1932).
Beckermann, “Determination of monovethylarsonic acid and dimethylarsinic acid by derivatization with thioglycolic acid methyl ester and gas-liquid chromatographic separation,” Analytica Chimica Acta, 135(1):77-84 (1982).
Beliles, “The Metals,” InPatty's Industrial Hygiene and Toxicology, fourth editionG.D. Clayton and F.E. Clayton, eds. John Wiley & Sons, Inc.: New York. pp. 1913-1925 (1994).
Calleja and Warrell, “Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia,” Curr. Oncol. Rep., 2:519-523 (2000).
Chen, et al., “6-thio-and-seleno-alpha-D-glucose esters of dimethylarsinous acid,” Carb. Res. 50:53-62 (1976).
Chen, et al., “Synthesis of 1- and 6-S and 1- and 6-Se-derivatives of 2-amino-2-deoxy-alpha/beta-D-glucopyrasone,” J. Chemical Soc, Perkin Trans., 1:2287-2293 (1980).
Cullen, et al., “The metabolism of methylarsine oxide and sulfide,” Applied Organometallic Chemistry, 3(1):71-78 (1989).
Cullen, et al., “The reaction of methylarsenicals with thiols: some biological implications,” Journal of Inorganic Biochemistry, 21(3):179-194 (1984).
Cuzick, et al., “Medicinal arsenic and internal malignancies,” Br. J. Cancer, 45:904-911 (1982).
Daniel, et al., “Dimethylarsinous Acid Esters of 1-Thio- and -Seleno-galactose, A New Class of Potential Carcinostatic Agents,” Phosphorus and Sulfur, 4:179-185 (1978).
Emran, et al., “Synthesis and biodistribution of radioarsenic labeled dimethylarsinothiols: derivatives of pennicillamine and mercaptoethanol,” International Journal of Nuclear Medicine and Biology, 11(3-4):259-261 (1984).
Forkner and McNair-Scott, “Arsenic as a therapeutic agent in chronic myeloid leukemia,” JAMA, 97(1):3-6 (1931).
Geissler, et al., “In vivo effects of arsenic trioxide in refractory acute myeloid leukemia other than acute promyelocytic leukemia,” Blood, 94:4230a (1999).
Goyer, “Toxic effects of metals” InCasarett and Doull's Toxicology: The Basic Science of Poisons, 5th edition. C.D. Klassen, ed. McGraw-Hill: New York, pp. 691-698 (1996).
Grignani, et al., “The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells,” Cell, 74:423-431 (1993).
Hosain, et al., “Synthesis of radioarsenic labeled dimethylchloroarsine for derivation of a new group of radiopharmceuticals,” International Journal of Applied Radiation and Isotopes, 33(12):1477-1478 (1982).
Hughes and Kenyon, “Dose-dependent effects on the disposition of monomethylarsonic acid and dimethylarsinic acid in the mouse after intravenous administration,” J. Toxicol. Environ. Health, 53(2):95-112 (1998).
IARC. Some metals and metallic compounds. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. vol. 23:39-141 (1980).
Ionov, et al., “Reaction of tertiary arsine sulfides with alkyl chlorocarbonates,” Zhurnal Obshchei Khimii, 46(11):2555-2558 (1976).
Kala, et al., “The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for bilary excretion of arsenic,” J. Biol. Chem., 275(43):33404-33408 (2000).
King and Ludford, “Relation between the constitution of arsenicals and their action on cell division,” Journal of the Chemical Society Abstracts, 2086-2088 (1950).
Kitamura, et al., “New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation,” Cancer Chemother Pharmacol., 40 (Suppl):S36-S41 (1997).
Knock, et al., “The use of selected sulfhydryl inhibitors in a preferential drug attack on cancer,” Surg. Gynecol. Obstet., 133:458-466 (1971).
Kober, et al., “Reaction of (dimethylamino)dimethylarsine with 1, 2-diols Reaction of (dimethylamino)dimethylarsine with 1, 2-diols,” Zeitschrift Fuer Anorganische Und Allgemeine Chemie, 406(1):52-61 (1974).
Konig, A., et al., “Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines,” Blood 90:562-570 (1997).
Lallemand-Breitenbach, et al., “Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia,” J. Exp. Med., 189:1043-1052 (1999).
Lam, et al., “Spectroscopic studies of arsenic (III) binding toEscherichia coliRI methyltransferase and to two mutants, C223S and W183F,” Biochemistry, 31(43):10438-10442 (1992).
Lin, et al., “Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase,” Chemical Research in Toxicology, 12(10):924-930 (1999).
Mester, et al., “Speciation of dimethylarsinic acid and monomethylarsonic acid by gas chromatography-mass spectrometry,” Jr. of Chromatography, 832(1+2):183-190 (1999).
Mountain, et al., “Chemotherapy studies in an animal tumor spectrum: II. Sensitivity of tumors to fourteen antitumor chemicals,” Cancer Res., 26:181-206 (1966).
Rivi, et al., “Organic arsenical melarsoprol shows growth suppressive activity via programmed cell death on myeloid and lymphoid leukemia derived cell lines,” Blood (Suppl), 88:68a (1996).
Rosenthal, et al., “The Synthesis and Characterization of Thio Sugar Esters of Diorganylarsinous Acids,” Phosphorus and Sulfur, 9:107-116 (1980).
Rousselot, et al., “Use of arsenic trioxide (As2O3) in the treatment of chronic myelogenous leukemia: In vitro and in vivo studies,” Blood, 94:4457a (1999).
Schoene, et al, “Speciation of arsenic-containing chemical warfare agents by gas chromatographic analysis after derivatization with thioglcolic acid methyl ester,” Journa
Gutsch Paul
Renzelmann Brian
Ropes & Gray LLP
Sullivan Daniel
Valenrod Yevegeny
Ziopharm Oncology, Inc.
LandOfFree
Compounds and methods for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726662